What is the frequency of vinorelbine Injection 10mg administration?
Oral Vinorelbine Injection 10mg should be taken at a dose of 60 mg/m(2) weekly for the first three weeks (cycle 1) and then 80 mg/m(2) weekly after that. If severe neutropenia develops during the first cycle, therapy is continued with 60 mg/m weekly dosages (2).
What is the best way to administer vinorelbine?
- Vinorelbine will be given to you as a drip (infusion) over the course of 5 to 30 minutes by your nurse.
- If you have vinorelbine as a drip, you can administer it as follows:
- a fine tube that enters through the skin of your chest and into a vein close by (cannula) a short thin tube that the nurse inserts into a vein in your arm or hand (central line). For more details Click Here.
What are the risks of taking vinorelbine?
Nausea, vomiting, tiredness, constipation, diarrhea, disorientation, muscular aches, joint pain, or discomfort at the injection site are all possible side effects. Any problems or adverse effects should be reported to your doctor or pharmacist as soon as possible. It’s possible that you’ll lose some hair temporarily. Normal hair growth should continue after the operation.
Is there a link between vinorelbine and peripheral neuropathy?
Mild to moderate peripheral neuropathy affects 7% to 31% of patients treated with Vinorelbine Injection 10mg, although severe toxicity has been recorded in a few cases and is notably linked to simultaneous or prior paclitaxel treatment.
Is vinorelbine linked to neuropathy?
The neurotoxicity of cumulative vinorelbine doses increased, and most patients experienced mild to moderate peripheral neuropathy. Neuropathic signs and symptoms were somewhat reversible after stopping vinorelbine medication.
What is the vinorelbine antidote?
There is no specific antidote that has been discovered. – In the event of infection-related problems, broad-spectrum antibiotic therapy may be required. There is no recognized antidote for vinorelbine overuse. Vinorelbine Injection 10mg belongs to the Vinca alkaloid family of cytostatic drugs.
When did vinorelbine become available?
Vinorelbine was developed in the 1980s by pharmacist Pierre Potier and his colleagues at the CNRS in France and was licensed to the Pierre Fabre Group’s oncology section. In 1989, the medicine was licensed in France for the treatment of non-small cell lung cancer under the trade name Navelbine.